Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
BHVN Biohaven Ltd
- Stocks
- Healthcare
- NYSE: BHVN
Price (delayed)
$16.21
Market cap
$1.66B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$9.29
Enterprise value
$1.59B
Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on development of therapies for neurological and immunoscience diseases that can change current treatment paradigms.
Highlights
The company's debt rose by 14% YoY but it fell by 6% QoQ
Biohaven's net income has plunged by 72% YoY and by 5% from the previous quarter
BHVN's quick ratio is down by 40% year-on-year and by 37% since the previous quarter
Key stats
What are the main financial stats of BHVN
Market
Valuations
Earnings
Shares outstanding
102.11M
Market cap
$1.66B
Enterprise value
$1.59B
Price to earnings (P/E)
N/A
Price to book (P/B)
6.38
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$923.43M
Net income
-$888.6M
EBIT
-$887.82M
EBITDA
-$879.17M
Free cash flow
-$649.01M
Per share
Balance sheet
Liquidity
EPS
-$9.29
EPS diluted
-$9.29
Free cash flow per share
-$6.37
Book value per share
$2.54
Revenue per share
$0
TBVPS
$4.31
Total assets
$458.95M
Total liabilities
$199.45M
Debt
$30.8M
Equity
$259.5M
Working capital
$218.72M
Debt to equity
0.12
Current ratio
2.33
Quick ratio
1.97
Net debt/EBITDA
0.08
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-164%
Return on equity
-257.1%
Return on invested capital
-336.5%
Return on capital employed
-301%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BHVN stock price
How has the Biohaven stock price performed over time
Intraday
2.72%
1 week
7.64%
1 month
-29.06%
1 year
-51.45%
YTD
-56.6%
QTD
-32.57%
Financial performance
How have Biohaven's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$923.43M
Net income
-$888.6M
Gross margin
N/A
Net margin
N/A
Biohaven's net income has plunged by 72% YoY and by 5% from the previous quarter
The company's operating income has shrunk by 71% YoY and by 4.3% QoQ
Price vs fundamentals
How does BHVN's price correlate with its fundamentals
Growth
What is Biohaven's growth rate over time
Valuation
What is Biohaven stock price valuation
P/E
N/A
P/B
6.38
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has declined by 35% year-on-year
The equity has declined by 39% since the previous quarter and by 14% year-on-year
The stock's P/B is 38% below its last 4 quarters average of 10.3
Efficiency
How efficient is Biohaven business performance
The ROE has plunged by 75% YoY and by 8% from the previous quarter
The ROA has contracted by 44% YoY and by 3% from the previous quarter
Biohaven's return on invested capital has decreased by 35% YoY
Dividends
What is BHVN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BHVN.
Financial health
How did Biohaven financials performed over time
The company's total assets is 130% higher than its total liabilities
The total liabilities has soared by 70% YoY and by 4.1% from the previous quarter
The current ratio has declined by 42% year-on-year and by 33% since the previous quarter
The company's debt is 88% lower than its equity
BHVN's debt to equity has surged by 50% since the previous quarter and by 33% year-on-year
The equity has declined by 39% since the previous quarter and by 14% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.